Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Laboratory Co. of America Holdings NYSE: LH. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
- Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
- Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
- Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.
Laboratory Co. of America Price Performance
Shares of LH traded up $3.07 during midday trading on Wednesday, hitting $235.72. 123,059 shares of the company traded hands, compared to its average volume of 621,494. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The firm has a market cap of $19.73 billion, a P/E ratio of 26.72, a PEG ratio of 1.71 and a beta of 1.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. The stock has a 50-day moving average of $244.45 and a 200-day moving average of $234.86.
Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. As a group, sell-side analysts predict that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.
Laboratory Co. of America Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th were paid a $0.72 dividend. The ex-dividend date was Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.22%. Laboratory Co. of America's dividend payout ratio is currently 32.65%.
Insider Transactions at Laboratory Co. of America
In related news, EVP Amy B. Summy sold 758 shares of Laboratory Co. of America stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $231.67, for a total transaction of $175,605.86. Following the sale, the executive vice president now directly owns 5,302 shares in the company, valued at $1,228,314.34. The trade was a 12.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $235,000.00. Following the completion of the transaction, the director now owns 12,722 shares of the company's stock, valued at approximately $2,989,670. This trade represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,258 shares of company stock valued at $3,753,177. Company insiders own 0.85% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on LH. StockNews.com lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler boosted their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Evercore ISI raised shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and lifted their price objective for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Barclays lowered their price target on Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating on the stock in a research report on Friday, February 7th. Finally, Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Laboratory Co. of America has an average rating of "Moderate Buy" and a consensus target price of $270.38.
Read Our Latest Stock Report on LH
Institutional Trading of Laboratory Co. of America
Institutional investors have recently modified their holdings of the company. Capital City Trust Co. FL lifted its holdings in Laboratory Co. of America by 1.5% in the 4th quarter. Capital City Trust Co. FL now owns 15,553 shares of the medical research company's stock worth $3,567,000 after buying an additional 223 shares during the period. Wealthcare Advisory Partners LLC lifted its stake in Laboratory Co. of America by 23.9% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company's stock worth $583,000 after acquiring an additional 490 shares during the period. Bryn Mawr Capital Management LLC lifted its stake in Laboratory Co. of America by 51.2% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 1,495 shares of the medical research company's stock worth $343,000 after acquiring an additional 506 shares during the period. Barclays PLC increased its position in Laboratory Co. of America by 11.8% during the 3rd quarter. Barclays PLC now owns 620,721 shares of the medical research company's stock valued at $138,718,000 after purchasing an additional 65,356 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Laboratory Co. of America by 7.0% in the 4th quarter. Nordea Investment Management AB now owns 1,052,927 shares of the medical research company's stock worth $243,321,000 after purchasing an additional 68,974 shares in the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
Laboratory Co. of America Company Profile
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Further Reading
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
